Chromatin regulatory mechanisms and therapeutic opportunities in cancer
Research over the past several decades has unmasked a major contribution of disrupted
chromatin regulatory processes to human disease, particularly cancer. Advances in genome …
chromatin regulatory processes to human disease, particularly cancer. Advances in genome …
The epigenomics of sarcoma
Epigenetic regulation is critical to physiological control of development, cell fate, cell
proliferation, genomic integrity and, fundamentally, transcriptional regulation. This …
proliferation, genomic integrity and, fundamentally, transcriptional regulation. This …
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
Abstract Development of candidate cancer treatments is a resource-intensive process, with
the research community continuing to investigate options beyond static genomic …
the research community continuing to investigate options beyond static genomic …
The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma
Synovial sarcoma (SS) is defined by the hallmark SS18-SSX fusion oncoprotein, which
renders BAF complexes aberrant in two manners: gain of SSX to the SS18 subunit and …
renders BAF complexes aberrant in two manners: gain of SSX to the SS18 subunit and …
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
L Jerby-Arnon, C Neftel, ME Shore, HR Weisman… - Nature medicine, 2021 - nature.com
Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18–SSX fusion, and is
characterized by low T cell infiltration. Here, we studied the cancer–immune interplay in SyS …
characterized by low T cell infiltration. Here, we studied the cancer–immune interplay in SyS …
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives
disease development. Targeting oncogenic fusion proteins presents an attractive …
disease development. Targeting oncogenic fusion proteins presents an attractive …
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo …
E Chan-Penebre, K Armstrong, A Drew… - Molecular cancer …, 2017 - AACR
The SWI/SNF complex is a major regulator of gene expression and is increasingly thought to
play an important role in human cancer, as evidenced by the high frequency of subunit …
play an important role in human cancer, as evidenced by the high frequency of subunit …
Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
M Linch, AB Miah, K Thway, IR Judson… - Nature reviews Clinical …, 2014 - nature.com
Soft-tissue sarcoma (STS) is a rare and heterogeneous group of tumours that comprise
approximately 1% of all adult cancers, and encompass over 50 different subtypes. These …
approximately 1% of all adult cancers, and encompass over 50 different subtypes. These …
The SS18-SSX oncoprotein hijacks KDM2B-PRC1. 1 to drive synovial sarcoma
Synovial sarcoma is an aggressive cancer invariably associated with a chromosomal
translocation involving genes encoding the SWI-SNF complex component SS18 and an SSX …
translocation involving genes encoding the SWI-SNF complex component SS18 and an SSX …
Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy
Oncogenesis in synovial sarcoma is driven by the chromosomal translocation t (X, 18; p11,
q11), which generates an in-frame fusion of the SWI/SNF subunit SS18 to the C-terminal …
q11), which generates an in-frame fusion of the SWI/SNF subunit SS18 to the C-terminal …